New antibody drug shows promise in early blood cancer trial

NCT ID NCT04540796

Completed Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a new drug called JNJ-75348780 in 147 people with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals were to check safety and find the right dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JNJ-75348780 (a bispecific antibody that targets CD3 and CD22 proteins on immune and cancer cells)
What this could lead to: If successful, this could lead to a new treatment option for people with certain blood cancers that have not responded to other therapies.
What could go wrong: This is an early Phase 1 trial focused on safety and dosing, so it is not yet known if the drug works. Side effects, including immune reactions, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia B-cell non-Hodgkin lymphoma diffuse large B-cell lymphoma follicular lymphoma lymphoma, non-Hodgkin, familial mantle cell lymphoma marginal zone lymphoma non-Hodgkin lymphoma Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL LYMPHOMA, NON-HODGKIN

Contacts and locations

Locations

Asan Medical Center

Seoul, 05505, South Korea
Austin Hospital

Heidelberg, 3084, Australia
CHRU de Lille Hopital Claude Huriez

Lille, 59037, France
CHU Nantes

Nantes, 44093, France
Carmel Medical Center

Haifa, 34362, Israel
Centre hospitalier Lyon-Sud

Pierre-Bénite, 69495, France
Chang-Gung Memorial Hospital, Kaohsiung

Kaohsiung City, 83301, Taiwan
China Medical University Hospital

Taichung, 40402, Taiwan
Clinica Univ. de Navarra

Pamplona, 31008, Spain
Hadassah Medical Center

Jerusalem, 9112001, Israel
Hosp Clinico Univ de Salamanca

Salamanca, 37007, Spain
Hosp Univ Fund Jimenez Diaz

Madrid, 28040, Spain
Hosp. Univ. Germans Trias I Pujol

Barcelona, 8916, Spain
Hospital de Vall D'Hebron

Barcelona, 08035, Spain
Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
Kings College Hospital

London, SE5 9RS, United Kingdom
Leicester Royal Infirmary

Leicester, LE1 5WW, United Kingdom
Linear Clinical Research Ltd

Nedlands, 6009, Australia
National Cheng Kung University Hospital

Tainan, 70403, Taiwan
National Taiwan University Hospital

Taipei, 10048, Taiwan
Plymouth Hospital NHS Trust

Plymouth, PL6 8DH, United Kingdom
Rambam Medical Center

Haifa, 31096, Israel
Samsung Medical Center

Seoul, 06351, South Korea
Seoul National University Hospital

Seoul, 03080, South Korea
Severance Hospital Yonsei University Health System

Seoul, 03722, South Korea
Sheba Medical Center

Ramat Gan, 74047, Israel
Taichung Veterans General Hospital

Taichung, 40705, Taiwan
Tel Aviv Sourasky MC

Tel Aviv, 6423906, Israel
The Catholic University of Korea Seoul St Marys Hospital

Seoul, 06591, South Korea
The Christie Nhs Foundation Trust

Manchester, M20 4BX, United Kingdom
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35233, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.